]>
IRCT2017071935183N1 IRCT 2017-08-07 isfahan university of medical science Comparing the effect of only bolus Eptifibatide with bolus plus infusion form of Eptifibatide on bleeding complications and consequences on myocardial infarct patients No Comparing the effect of receiving only bolus dose Eptifibatide with bolus plus infusion strategy on bleeding complications and consequences after Percutaneous Coronary Intervention (PCI) on Myocardial Infarct (MI) patients 2017-07-23 anticipated 176 Complete https://irct.ir/trial/26664 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: No. N/A myocardial infarction. Intervention 1: the first group is received a bolus dose of 180 mcg/kg Eptifibatide (Integrilin company)from peripheral vein during 8 minutes, immediately before PCI and after that PCI is done.After PCI. all patients received 75 mg clopidogrel for every 12 hours as a routine treatment. Intervention 2: Patients in the second group received routine treatment in addition with 10-hours infusion of 2 mcg/kg/min Eptifibatide with maximum dose of 15 mcg/hour and if patients creatinine clearance< 50 mg/min, about 1 mcg/kg/min of Eptifibatide were infused and if patients had creatinine>4, they were excluded from study. All patients were received 75 mg clopidogrel every 12 hours as a routine treatment.
public hasan shemirani
isfahan, bozorgmehr brdige, abshare sevom street, shahid chamran hospital
isfahan Iran (Islamic Republic of) +98 31 3260 0961 shemirani@med.mui.ac.ir isfahan university of medical science scientific hasan shemirani
isfahan, bozorgmehr bridge, abshare sevom street, shahid chamran hospital
isfahan Iran (Islamic Republic of) +98 31 3260 0961 shemirani@med.mui.ac.ir isfahan university of medical science Iran (Islamic Republic of) Inclusion criteria were as followed: 1) age more than 18 years, 2)having elevation in Troponin enzyme level, 3) having electrocardiogram changes due to infarction, 4)candidate for angioplasty and percutaneous coronary intervention, 5) having no contraindication for administrating Eptifibatide, 6) patient's willingness to participate in this study Exclusion criteria were as followed:1) Patient's unwillingness to continue his/ her participation, 2)history of stroke, 3)treating with anti coagulant medications, 4)using medications that has interaction with Eptifibatide, 5) have not experience PCI, 6)have experienced thrombectomy, 7) having sensitivity to Eptifibatide, 8) having uncontrolled hypertension, 9) dialysis patients 18 years 90 years Both I21 E1, E2, E3, E4, E9 Treatment - Drugs Treatment - Drugs the first group is received a bolus dose of 180 mcg/kg Eptifibatide (Integrilin company)from peripheral vein during 8 minutes, immediately before PCI and after that PCI is done.After PCI. all patients received 75 mg clopidogrel for every 12 hours as a routine treatment. Patients in the second group received routine treatment in addition with 10-hours infusion of 2 mcg/kg/min Eptifibatide with maximum dose of 15 mcg/hour and if patients creatinine clearance< 50 mg/min, about 1 mcg/kg/min of Eptifibatide were infused and if patients had creatinine>4, they were excluded from study. All patients were received 75 mg clopidogrel every 12 hours as a routine treatment Incidence of hematoma. Timepoint: immediately after intervention, 24, 48,72 and 96 hours after intervention. Method of measurement: observation. Incidence of bleeding. Timepoint: immediately after intervention, 24, 48,72 and 96 hours after intervention. Method of measurement: observation. Needs for additional coronary intervention. Timepoint: one week after intervention. Method of measurement: physical examination. Death. Timepoint: one week after intervention. Method of measurement: observation. isfahan university of medical science Approved 2010-08-20 Isfahan university of medical science isfahan, hezar jarib street, isfahan university of medical sciene isfahan Iran (Islamic Republic of)